GO:0070345 negative regulation of fat cell proliferation: Signaling Pathways, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070345 defines any biological process that stops or decreases the rate or extent of fat cell (adipocyte) proliferation.
• Adipocyte proliferation is tightly linked to obesity, metabolic disease, and cancer progression, making its negative regulation a key research focus.
• Key signaling pathways include RUNX1T1-mediated cell fate control, EPAS1-driven metabolic adaptation, and cytokine signaling such as CXCL8.
• Experimental models for studying this process include CRISPR knockout, point mutation, knock-in, and overexpression cell lines.
• Dysregulation of negative regulators of adipocyte proliferation contributes to obesity, osteoarthritis, and triple-negative breast cancer.
• EDITGENE provides CRISPR-based services to dissect the causal roles of genes in negative regulation of fat cell proliferation.
Description
The Gene Ontology term GO:0070345, negative regulation of fat cell proliferation, describes any process that stops or decreases the rate or extent of fat cell proliferation. Fat cells, or adipocytes, are central to energy homeostasis, and their uncontrolled expansion is a hallmark of obesity and related metabolic disorders. Understanding the molecular brakes on adipocyte proliferation is therefore critical for developing therapeutic strategies. Recent studies have highlighted the importance of metabolic and inflammatory signals in controlling adipocyte numbers. For example, pro-inflammatory cytokines such as TNF-alpha and IL-6 can modulate adipocyte biology and contribute to osteoarthritis pathogenesis. Additionally, cancer-associated adipocytes secrete factors like CXCL8 that promote tumor progression, underscoring the need to understand how adipocyte proliferation is negatively regulated in the tumor microenvironment. This article synthesizes current knowledge on the mechanisms, genes, and research methods relevant to GO:0070345, providing a resource for researchers aiming to manipulate this process experimentally.
negative regulation of fat cell proliferation At A Glance
| GO ID | GO:0070345 |
|---|---|
| GO term | negative regulation of fat cell proliferation |
| Ontology | biological_process |
| Synonym | down regulation of fat cell proliferation, down-regulation of fat cell proliferation, downregulation of fat cell proliferation, inhibition of fat cell proliferation, negative regulation of adipocyte proliferation, negative regulation of adipose cell proliferation |
| Major function | Stops or decreases the rate or extent of fat cell proliferation |
| Related processes | Adipogenesis, cell cycle arrest, metabolic regulation, inflammatory signaling |
| Key regulators | RUNX1T1, EPAS1, CXCL8, pro-inflammatory cytokines |
| Disease relevance | Obesity, osteoarthritis, triple-negative breast cancer, metabolic disorders |
What Is GO:0070345?
GO:0070345 is defined as any biological process that stops or decreases the rate or extent of fat cell proliferation. In simpler terms, it encompasses all molecular events that put the brakes on the multiplication of fat cells, preventing excessive adipose tissue expansion. This regulation can occur through cell-intrinsic mechanisms, such as cell cycle inhibitors, or through extrinsic signals from the microenvironment, including cytokines and metabolic cues.
Why Is negative regulation of fat cell proliferation Important in Cell Biology?
Negative regulation of fat cell proliferation is crucial for maintaining metabolic health and preventing pathological adipose tissue expansion. Dysregulation of this process contributes to obesity, which is a major risk factor for type 2 diabetes, cardiovascular disease, and osteoarthritis. Moreover, in cancer, adipocytes within the tumor microenvironment can promote malignancy, and understanding how to inhibit their proliferation may enhance anti-tumor immunity. Thus, deciphering the molecular players in GO:0070345 offers potential therapeutic targets for a range of diseases.
• Prevents excessive adipose tissue expansion, reducing obesity risk.
• Modulates metabolic homeostasis and energy balance.
• Influences osteoarthritis pathogenesis via pro-inflammatory cytokines.
• Affects cancer progression, particularly triple-negative breast cancer.
• Regulates skeletal cell fate and bone remodeling.
• Impacts angiogenesis and wound repair through exosomal signals.
• Controls cell fate decisions via RUNX1T1.
• Mediates endothelial fatty acid uptake and atherosclerosis.
• Provides targets for anti-obesity therapies.
• Serves as a model for studying cell cycle regulation in adipocytes.
What Happens During negative regulation of fat cell proliferation?
Initiation by Extrinsic Signals
In simple terms: External signals tell fat cells to stop dividing.
Negative regulation of fat cell proliferation often begins with extrinsic cues such as pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) that bind to receptors on adipocytes or their precursors. These signals activate intracellular cascades that ultimately inhibit cell cycle progression. For instance, in osteoarthritis, pro-inflammatory cytokines link obesity to joint inflammation and may suppress adipocyte proliferation in the joint microenvironment. Similarly, cancer-associated adipocytes secrete CXCL8, which can modulate proliferation in a context-dependent manner.
Intracellular Signaling Cascades
In simple terms: Inside the cell, a chain of molecular events relays the stop signal.
Upon receptor activation, intracellular pathways such as the RUNX1T1-mediated transcriptional program can be engaged to alter cell fate decisions. RUNX1T1 functions as a transcriptional corepressor that can inhibit adipocyte differentiation and proliferation. Additionally, metabolic sensors like EPAS1 (HIF-2alpha) respond to oxygen and fatty acid levels, attenuating atherosclerosis initiation by modulating endothelial fatty acid uptake, which indirectly affects adipocyte proliferation. These cascades often converge on cell cycle regulators like cyclins and CDKs.
Cell Cycle Arrest
In simple terms: The cell cycle machinery is halted, preventing division.
The ultimate step in negative regulation of fat cell proliferation is the inhibition of cell cycle progression. This can occur through upregulation of cyclin-dependent kinase inhibitors (e.g., p21, p27) or downregulation of cyclins and CDKs. Although specific studies on adipocyte cell cycle arrest are limited in the provided citations, general mechanisms of cell fate regulation by RUNX1T1 suggest its involvement in halting proliferation. In the context of obesity, harnessing adipogenesis to prevent obesity may involve promoting cell cycle exit in adipocyte precursors.
Metabolic Modulation
In simple terms: Changes in cellular metabolism reinforce the stop signal.
Metabolic regulation of skeletal cell fate and function highlights the interplay between energy metabolism and cell proliferation. For example, EPAS1 attenuates atherosclerosis initiation by enhancing endothelial fatty acid uptake, which may alter lipid availability for adipocytes and indirectly suppress their proliferation. Similarly, exosomal DMBT1 from urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis, a process that can influence adipocyte behavior in the wound microenvironment.
Integration with Tissue Microenvironment
In simple terms: The surrounding tissue context fine-tunes the stop signal.
Negative regulation of fat cell proliferation does not occur in isolation; it is influenced by the tissue microenvironment. In cancer, cancer-associated adipocytes interact with tumor cells, and targeting adipocyte-derived CXCL8 can inhibit triple-negative breast cancer progression and enhance immunotherapy efficacy. This suggests that the microenvironment can either promote or inhibit adipocyte proliferation. In neuromuscular disorders, muscle satellite cell dysfunction may alter the local milieu, potentially affecting adipocyte proliferation.
Key Genes Involved in GO:0070345 negative regulation of fat cell proliferation
The following genes and proteins have been implicated in the negative regulation of fat cell proliferation or related processes, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RUNX1T1 | Transcriptional corepressor regulating cell fate | Involved in cell fate decisions, potential inhibitor of adipocyte proliferation |
| EPAS1 | Hypoxia-inducible factor 2alpha, metabolic sensor | Attenuates atherosclerosis by modulating fatty acid uptake, may affect adipocyte proliferation |
| CXCL8 | Pro-inflammatory chemokine | Secreted by cancer-associated adipocytes, promotes tumor progression; targeting it inhibits TNBC |
| TNF | Pro-inflammatory cytokine | Links obesity and osteoarthritis, may suppress adipocyte proliferation |
| IL6 | Pro-inflammatory cytokine | Contributes to osteoarthritis and metabolic inflammation |
| DMBT1 | Exosomal protein from stem cells | Facilitates diabetic wound repair by promoting angiogenesis |
| PPARG | Master regulator of adipogenesis | Not directly cited but central to adipocyte biology; negative regulation may involve PPARG inhibition |
| CEBPA | Transcription factor for adipogenesis | Key adipogenic factor, potential target for negative regulation |
| WNT10B | Wnt family member | Inhibits adipogenesis; may negatively regulate fat cell proliferation |
| GATA2 | Transcription factor | Inhibits adipocyte differentiation; potential negative regulator |
| KLF2 | Kruppel-like factor | Inhibits adipogenesis; may reduce fat cell proliferation |
| CHOP | ER stress-induced transcription factor | May mediate inhibition of adipocyte proliferation under stress |
| SIRT1 | NAD-dependent deacetylase | Modulates adipogenesis and may inhibit fat cell proliferation |
| AMPK | Energy sensor kinase | Inhibits adipocyte proliferation under low energy conditions |
| mTOR | Growth and proliferation regulator | Inhibition of mTOR suppresses adipocyte proliferation |
| TGFB1 | Transforming growth factor beta | Inhibits adipocyte proliferation in some contexts |
| IFNG | Interferon gamma | Pro-inflammatory cytokine that can suppress adipocyte proliferation |
| LIF | Leukemia inhibitory factor | May inhibit adipocyte proliferation via STAT3 |
How Is negative regulation of fat cell proliferation Regulated?
The negative regulation of fat cell proliferation is controlled by a complex network of signaling pathways. Key regulators include pro-inflammatory cytokines such as TNF and IL-6, which can activate intracellular cascades that inhibit cell cycle progression. The RUNX1T1 transcriptional corepressor plays a role in cell fate decisions, potentially suppressing adipocyte proliferation. Metabolic sensors like EPAS1 respond to oxygen and lipid levels, influencing endothelial fatty acid uptake and indirectly affecting adipocyte proliferation. Additionally, the mTOR pathway, a central regulator of cell growth, when inhibited, can lead to reduced adipocyte proliferation. AMPK, an energy sensor, also negatively regulates adipocyte proliferation under low-energy conditions. These pathways are often dysregulated in obesity and cancer, highlighting their therapeutic potential.
negative regulation of fat cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCL8 | Triple-negative breast cancer | Knockout of CXCL8 in cancer-associated adipocytes, co-culture with TNBC cells |
| EPAS1 | Atherosclerosis | Endothelial-specific knockout or overexpression in mouse models of disturbed flow |
| RUNX1T1 | Cell fate dysregulation | Knockout or overexpression in adipocyte precursor cells to assess proliferation |
| TNF | Obesity and osteoarthritis | TNF knockout mice or adipocyte-specific overexpression |
| DMBT1 | Diabetic wound repair | Exosomal DMBT1 treatment in diabetic wound models |
Obesity and Metabolic Disorders
Obesity results from an imbalance between energy intake and expenditure, often involving excessive adipocyte proliferation and hypertrophy. Negative regulation of fat cell proliferation is critical to prevent adipose tissue expansion. Pro-inflammatory cytokines like TNF and IL-6, which link obesity to osteoarthritis, can also modulate adipocyte proliferation. Harnessing adipogenesis to prevent obesity is a therapeutic strategy that may involve promoting negative regulators of fat cell proliferation.
Osteoarthritis
Osteoarthritis is a degenerative joint disease exacerbated by obesity. Pro-inflammatory cytokines act as a link between obesity and osteoarthritis, and they may influence adipocyte proliferation in the joint environment. Understanding how these cytokines negatively regulate fat cell proliferation could lead to new treatments for osteoarthritis.
Triple-Negative Breast Cancer
Cancer-associated adipocytes promote tumor progression, and targeting adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances anti-PD-1 immunotherapy efficacy. This suggests that negative regulation of fat cell proliferation in the tumor microenvironment could be a therapeutic strategy.
Atherosclerosis
EPAS1 attenuates atherosclerosis initiation at disturbed flow sites through endothelial fatty acid uptake. This metabolic regulation may indirectly affect adipocyte proliferation, linking negative regulation of fat cell proliferation to cardiovascular disease.
From negative regulation of fat cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate fat cell proliferation? | CRISPR knockout of gene X in preadipocytes, followed by proliferation assays |
| Does a specific point mutation in gene Y affect its function? | CRISPR point mutation knock-in in adipocyte cell lines |
| Does overexpression of gene Z inhibit adipocyte proliferation? | CRISPR knock-in of a constitutive promoter or cDNA overexpression |
| How does tagging gene W affect its localization and function? | CRISPR knock-in of a fluorescent tag (e.g., GFP) |
| What is the role of gene V in cancer-associated adipocytes? | CRISPR knockout in cancer-associated adipocytes co-cultured with cancer cells |
| Does gene U regulate adipocyte proliferation in vivo? | Adipocyte-specific knockout mouse models |
How to Study the negative regulation of fat cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on proliferation | Identify genes that negatively regulate fat cell proliferation |
| RNA-seq | Transcriptomic changes | Discover pathways altered by negative regulators |
| EdU/BrdU incorporation | DNA synthesis rate | Quantify adipocyte proliferation |
| Co-IP/MS | Protein interactions | Map complexes involving RUNX1T1 or other regulators |
| Western blot | Protein expression levels | Validate knockout or overexpression efficiency |
| Luciferase reporter | Transcriptional activity | Assess promoter regulation by transcription factors |
| Flow cytometry | Cell cycle distribution | Determine cell cycle arrest |
| Exosome isolation | Exosomal cargo | Study DMBT1-mediated effects on wound repair |
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that negatively regulate fat cell proliferation. Libraries targeting epigenetic regulators, kinases, or transcription factors can be introduced into preadipocytes, followed by selection for cells that continue to proliferate. Hits are validated by individual gene knockout.
RNA Sequencing (RNA-seq)
RNA-seq of adipocytes under conditions that inhibit proliferation can reveal transcriptomic changes, including upregulation of cell cycle inhibitors and downregulation of proliferative genes. Comparing wild-type and knockout cells can identify pathways controlled by specific negative regulators.
Proliferation Assays
EdU incorporation, BrdU labeling, or real-time cell analysis (RTCA) can measure the rate of adipocyte proliferation. These assays are used to confirm the effects of genetic manipulations (knockout, overexpression) on fat cell proliferation.
Protein-Protein Interaction Studies
Co-immunoprecipitation (co-IP) and mass spectrometry can identify interaction partners of negative regulators like RUNX1T1. Understanding these interactions may reveal how they inhibit proliferation.
How CRISPR Can Be Used to Study GO:0070345 negative regulation of fat cell proliferation
Knockout
CRISPR knockout of candidate genes in preadipocytes or adipocyte cell lines can determine whether the gene is required for negative regulation of fat cell proliferation. For example, knocking out RUNX1T1 may lead to increased proliferation if it normally acts as a brake. Similarly, knocking out CXCL8 in cancer-associated adipocytes could affect their proliferation and interaction with cancer cells.
Point Mutation
CRISPR point mutation knock-in can model specific amino acid changes in genes like EPAS1 to study their impact on protein function and adipocyte proliferation. This is useful for mimicking human polymorphisms associated with metabolic disease.
Knock-in
Knock-in of reporter genes (e.g., GFP) or tags allows visualization of endogenous protein localization and dynamics in live adipocytes. This can reveal how negative regulators like RUNX1T1 are distributed during proliferation arrest.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can force high expression of candidate negative regulators to test their ability to inhibit fat cell proliferation. For instance, overexpressing EPAS1 in endothelial cells attenuated atherosclerosis in a mouse model.
How EDITGENE Supports negative regulation of fat cell proliferation Research
Researchers studying negative regulation of fat cell proliferation-related genes often need to determine whether a candidate gene is causally involved in halting adipocyte division. EDITGENE provides a comprehensive suite of CRISPR services to enable such investigations, from knockout to overexpression and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of fat cell proliferation research.
Frequently Asked Questions About negative regulation of fat cell proliferation
What is GO:0070345?
GO:0070345 is the Gene Ontology term for negative regulation of fat cell proliferation, defined as any process that stops or decreases the rate or extent of fat cell proliferation.
What genes are involved in negative regulation of fat cell proliferation?
Key genes include RUNX1T1, EPAS1, CXCL8, TNF, IL6, and DMBT1, among others.
How is fat cell proliferation negatively regulated?
It is regulated by extrinsic signals like pro-inflammatory cytokines, intracellular cascades involving RUNX1T1, and metabolic sensors such as EPAS1, leading to cell cycle arrest.
Why is negative regulation of fat cell proliferation important?
It prevents excessive adipose tissue expansion, reducing obesity and related diseases like osteoarthritis and cancer progression.
What diseases are associated with dysregulation of this process?
Obesity, osteoarthritis, triple-negative breast cancer, and atherosclerosis are linked to altered negative regulation of fat cell proliferation.
What experimental models are used to study GO:0070345?
CRISPR knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening, are commonly used.
How can CRISPR help study negative regulation of fat cell proliferation?
CRISPR allows precise genetic manipulation to test the causal role of specific genes in inhibiting adipocyte proliferation.
What is the role of RUNX1T1 in fat cell proliferation?
RUNX1T1 is a transcriptional corepressor that regulates cell fate and may inhibit adipocyte proliferation.
How does EPAS1 affect fat cell proliferation?
EPAS1 attenuates atherosclerosis by modulating endothelial fatty acid uptake, which may indirectly suppress adipocyte proliferation.
What services does EDITGENE offer for this research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services to study negative regulation of fat cell proliferation.
Conclusion
Negative regulation of fat cell proliferation (GO:0070345) is a critical biological process that controls adipose tissue expansion and impacts diseases ranging from obesity to cancer. Understanding its molecular mechanisms and key regulators offers therapeutic opportunities. EDITGENE's CRISPR services empower researchers to dissect these pathways with precision, accelerating discoveries in metabolic and cancer biology.
References
- 1. Stegen S et al.. 2024. Metabolic regulation of skeletal cell fate and function.. Nat Rev Endocrinol 20(7):399-413 PMID: 38499689
- 2. Wang T et al.. 2018. Pro-inflammatory cytokines: The link between obesity and osteoarthritis.. Cytokine Growth Factor Rev 44:38-50 PMID: 30340925
- 3. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 4. Chen CY et al.. 2018. Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis.. Theranostics 8(6):1607-1623 PMID: 29556344
- 5. Huang R et al.. 2023. Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy.. Cell Death Dis 14(10):703 PMID: 37898619
- 6. Hu N et al.. 2022. RUNX1T1 function in cell fate.. Stem Cell Res Ther 13(1):369 PMID: 35902872
- 7. Pirri D et al.. 2024. EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake.. Circ Res 135(8):822-837 PMID: 39234692
- 8. Haider N et al.. 2019. Harnessing adipogenesis to prevent obesity.. Adipocyte 8(1):98-104 PMID: 30848691
